Virtual Assay is used to perform simulations of drug effects in populations of human ventricular cells, and to predict potential side effects of the drugs on the human heart. Virtual Assay has been designed to be accessible by everyone, including people with little or no expertise in computer modelling and simulations. The target users are mainly pharmaceutical companies and academia. In industry, the main application would be for drug safety testing during pre-clinical drug development. In academia, it can be used both for research and teaching. Virtual Assay is licenced through Oxford University Innovation.
A free academic licence and a commercial licence are available, and they can be requested at: https://innovation.ox.ac.uk/licence-details/virtual-assay-drug-screening-software-v-3-0/.
- Passini E et al. 2017, Human in silico drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity. DOI
- Britton O et al. 2013, Experimentally−calibrated population of models predicts and explains inter−subject variability in cardiac cellular electrophysiology. DOI